Generation Lab’s Unnamed Shot Runs on Drugs It Cannot Own

Generation Lab is offering a weekly injection of two existing drugs that it says can make human blood act young again. The mix is called 1 Generation. Chief executive Alina Su, who is 26, told MIT Technology Review that a celebrity wait list is already long and that “this first longevity therapeutic in the human body is here and it’s actually working.”

The company will not say which drugs they are. That refusal is the business model as much as the science, because Generation Lab does not own the molecules and wants a short run of FDA protection plus a private clinic channel before copycats show up.

A Weekly Shot and a Celebrity Waitlist

Antonio Regalado, writing in MIT Technology Review on August 27, described a pitch aimed at “longevity influencers,” including an offer to join a “private cohort” under physician watch. A company fact sheet, he reported, says the injection “blocks the systemic spread of aging in the bloodstream, reawakens the body’s own repair mechanism and restores health and youth to multiple tissues.”

Su framed it as scarce. “There’s a long wait list including a lot of celebrities, well-known people, people who you have heard of,” she told him on a conference call. Matt Cook, founder of the BioReset Medical clinic network, told Regalado that his office had started getting calls from “high-end doctors, venture capitalists, and people in this community who are kind of biohackers.”

The people already injecting are insiders. Irina Conboy, Generation Lab’s scientific founder, has been taking the mix for about two months and says she feels better and more energetic. So have Su, Conboy’s husband and collaborator Michael Conboy, and Cook. A public-relations spreadsheet sent to MIT listed improved vision in a 64-year-old woman, longer landscaping sessions, longer badminton games, a stronger hand grip, “better erections than with Viagra,” and “increased bowel movements.”

In a July conversation later posted as video, Conboy described the human protocol as a weekly shot under the skin, in the same family of routine as today’s GLP-1 pens, given as eight doses with heavy blood sampling along the way. She said she had taken four of the eight shots at that point. Cook says the mix is prescribed and given by clinic staff, not sold as a consumer kit.

The larger study Su says is coming would enroll a hundred people or more, led in part by longevity doctors who already sell cash-pay treatments. MIT later corrected an earlier line: patients will not pay to join that sponsored trial, though they can still pay a doctor for the drugs outside it. Generation Lab is hosting an invite-only event today, August 28, with Harvard geneticist George Church and researchers from Anthropic on the bill. Church told MIT by email that he too was offered the mix.

Conboy Already Published a Two-Drug Mix

The secrecy would be easier to defend if the scientific trail were blank. It is not. Conboy spent two decades at the University of California, Berkeley, on parabiosis, the surgical joining of old and young circulations, and then on a simpler idea: old blood is the problem. “Old blood dominates,” she has said, meaning a single exchange of aged plasma can drag a younger animal down.

In 2020 her group showed that they could get the youth effect without young donors. They replaced half the plasma with saline-albumin in old mice, a “neutral” exchange that matched or beat pairing with a young animal on muscle repair, liver fat, and new neurons in the hippocampus. Human therapeutic plasma exchange, already FDA-cleared for other diseases, became the clinical cousin of that experiment.

The next step, Conboy has said in talks, was to turn dilution into a shot. The published candidate is not a mystery molecule. It is oxytocin, a hormone that falls with age, plus a low dose of an Alk5 inhibitor that turns down TGF-beta, a pathway that rises with age and pushes tissue toward scar and inflammation. In 2019 her lab reported that the pair, at a tenth the Alk5-blocker dose used alone, revived muscle, liver, and brain in old mice after a week.

On August 21, 2025, Aging-US published the lifespan follow-up. Frail mice 25 months old, roughly 75 in human years, got the mix by injection on a two-weeks-on, two-weeks-off cycle. Treated males showed a 73 percent remaining-life extension in frail male mice from the start of treatment, and a 14 percent rise in median lifespan counted from birth. They also ran longer, hung on a wire longer, and remembered objects better. Females did not live longer. Generation Lab has not said whether 1 Generation is this mix. The overlap in story, mechanism, and injection schedule is the part the company leaves hanging.

Cook, who prescribed the human combo and then took it, said his starting confidence “was a zero” because “it’s two safe, generic drugs that are not even longevity drugs.” He also said the effect did not match either drug on its own. That is either a clue that the pair is doing something new, or a reminder that open-label energy in a friend group is a weak instrument.

The $8,000 Procedure the Shot Is Meant to Replace

If a weekly generic mix works, the first business it hits is not a Big Pharma franchise. It is the plasma chair. After the 2020 mouse paper, longevity clinics copied the method as a wellness product. Jeffrey Gladden, a Texas longevity doctor who later signed on to Generation Lab’s study, told MIT he flew to California to meet Conboy and to have the procedure himself. MIT put the cash price at up to $10,000 a session.

Published clinic menus now cluster in a similar band. Dobri Kiprov’s Global Apheresis in Mill Valley, a practice tied to Conboy’s human samples, has listed a session at $8,000, with series pricing down to $6,000, and in 2024 the San Francisco Standard reported a every-two-months plan that ran to $36,000 a year. Other U.S. wellness pages quote $4,500 to $15,000 depending on how much plasma is swapped and whether immunoglobulin is added after. Insurance almost never pays when the indication is aging.

What the chair is selling

• The swap: One plasma volume comes out and 5% albumin goes in, sometimes with a small immunoglobulin infusion after, as in Conboy’s 2022 GeroScience clinical paper.
• The pitch: Dilute the age-raised signals in old plasma rather than infuse young-donor blood, which is the step that got startups such as Ambrosia into FDA trouble.
• The limit: The reset is transient, the session is slow, and the supply chain is albumin, nursing time, and an apheresis machine, not a vial in a fridge.

Young-blood companies that tried to bottle the 2005 parabiosis story have not shipped a hit. Elevian, a Harvard-linked startup, had raised about $40 million by 2024, per the San Francisco Standard. Alkahest’s plasma-fraction drug GRF6019 was reported as safe in small Alzheimer’s studies without a clean cognitive win. A shot that clinics can already prescribe, if it holds up, is cheaper to deliver than any of those machines or fractions. It is also much easier to copy.

Why Generation Lab Will Not Name the Molecules

Pressed on the names, Su told MIT the holdback is to stop imitators. That sentence is the whole regulatory strategy. The FDA’s Hatch-Waxman rules give a company that runs new human trials on a new use, new mix, or new form of already approved drugs a short protected window. The agency’s own explainer lists three years of new clinical investigation exclusivity when those trials were essential to approval, far short of the five years that attach to a brand-new chemical. A 505(b)(2) application can lean on the old safety files and add only the new clinical work.

Three years is not a patent on oxytocin. It is not a patent on an Alk5 blocker that cancer researchers have used for years. It is a pause on FDA approval of a rival that wants to rely on Generation Lab’s study to sell the same labeled use. Compounding clinics and off-label prescribers do not need that label. They need a recipe. Keeping the recipe inside a “private cohort” delays the copy, and it also delays any outsider who wants to check the claim.

Regalado wrote that he would not take the drugs until he knew what they were. That is the rational consumer position, and it is exactly what a three-year exclusivity race cannot afford. The company needs believers, clinic inventory, and trial data on a clock that starts only after approval, not after a press dinner.

Clinics, Influencers, and a Three-Year FDA Clock

Generation Lab is not a garage biotech that only has a syringe. It is a diagnostics company with a drug story bolted on, and the diagnostic is how the syringe reaches patients. The live site now says it is trusted by 750+ clinics and reports 460 biomarkers across 21 organ systems from a needle-free blood draw. In October 2025 the company announced an $11 million seed round led by Accel, taking total funding to $15 million, with Samsung Next and funds tied to Steve Aoki, Giannis Antetokounmpo, and Simu Liu in the round.

Accel partner Kerry Wang wrote that SystemAge uses a small at-home sample to score organ-by-organ biological age and that each report comes with recommendations including therapeutic plasma exchange, plus supplements and workouts. Fortune, reporting the round, put the test at $490. The same clinic rolodex that already sells TPE is the natural shelf for a weekly shot that claims to replace TPE. Gladden told MIT he was “skeptical and optimistic at the same time,” and that his Texas clinic would join the study.

On X, the public conversation around Generation Lab is still mostly about that test, not about 1 Generation. Longevity scientist Matt Kaeberlein hosted Conboy and Su on his podcast in late July and treated the fight over how aging should be measured, including a debate on rapamycin, as the mature argument. The MIT story itself drew little more than a shrug in replies. The wait list Su described is being built in rooms that do not need a trending topic.

How the company got to a syringe

1. 2005: Conboy’s heterochronic parabiosis work showed that joining a young mouse’s circulation to an old one restored healing in the old animal.
2. 2020: Her group’s neutral blood exchange paper showed saline plus 5% albumin could match those benefits without young blood.
3. 2022: A GeroScience clinical paper with Kiprov reported that repeated human plasma exchange shifted blood markers of inflammation and aging, with effects tracked across months.
4. August 21, 2025: The OT+A5i mouse lifespan paper reported the male-only remaining-life gain and a female null on lifespan.
5. October 23, 2025: Generation Lab closed the Accel-led seed around SystemAge, then at 275-plus clinics and 19 organ scores.
6. Late 2025: Conboy left Berkeley full time for the company, which had been selling the aging test and still wanted a drug that mimicked plasma exchange.
7. June 2026: SystemAge 2.1 added separate female and male versions, 21 systems, and a claim of 99% accuracy across 1,605 test cases, with Su citing 750-plus clinics in 18 countries.
8. Summer 2026: Insiders began weekly injections; MIT published the influencer pitch on August 27; the Church event is today.

That sequence is a diagnostics firm using its clinic graph as a distribution system for an unbranded combo, then asking FDA for a short exclusive label if the trial works. It is also a firm whose own test still points some patients toward the $8,000 chair the shot is supposed to retire.

The Mouse Results Stopped at Males

The 2025 paper is the strongest published support for the idea that two cheap agents can stand in for young blood, and it is also the strongest warning label. Fourteen old males got OT+A5i and 12 got vehicle. Treated males lived 221.1 extra days from first injection against 127.3 days in controls, a 73.73% gain in remaining life; median remaining life was 240.5 days against 93.5. The death hazard in controls was 2.868 times that of treated males. Ten old females got the mix and 13 got vehicle. There was no lifespan improvement. The female survival curves did not separate in the authors’ test (p = 0.1904).

A one-week course still made the blood-protein “noise” of both sexes look younger. After four months, only males kept that youthful blood profile. The authors wrote that middle-aged females did show a fertility benefit, which is a different endpoint from living longer. They do not know why the sexes split. Anyone translating that paper into a celebrity cohort that includes a 64-year-old woman reporting better vision is running ahead of the animal data on the claim that matters most, which is aging itself.

Conboy’s own screening tool, a microfluidic chip that bathes human cells in old serum, is how she says she picked a mix that “allows human cells to remain young even when they are in the presence of old people’s blood serum.” That is a cell assay, not a controlled human aging trial. The insider spreadsheet is not one either.

Matt Cook Started With Zero Confidence

Cook is the hinge between Conboy’s lab story and the cash-pay channel. He told MIT he first agreed to prescribe the mix to Conboy and a few people in the same Silicon Valley longevity circle. He is also the doctor whose clinics sell stem-cell injections and whose 2021 webinar, covered by the same magazine, put nebulized amniotic fluid among products the FDA had listed as fraudulent covid-19 treatments. He is now a trial lead for a drug whose names he cannot advertise.

My confidence this was going to work was a zero. Like, I did not believe it was actually going to work.

Matt Cook, founder of BioReset Medical, in an interview with MIT Technology Review

After weekly shots he described a day of mental clarity that then stretched across several days. Other subjects, he said, lost old aches and felt a broad lift “that doesn’t really match what either of the drugs do.” He still has “many more questions than I have answers” and still does not fully understand the mechanism. People are “clamoring for it,” he said, which is the sound of a market that has already decided the evidence bar is optional.

Tonight’s guest list, with Church and Anthropic researchers in the room, is meant to make that clamoring feel like a scientific debut. Church has spent years arguing that biology is becoming programmable; Anthropic’s chief, Dario Amodei, has said in other venues that AI will crush disease on a short clock. Neither claim names the two drugs in the syringe. Until someone does, 1 Generation is a weekly appointment, a three-year FDA wager, and a published mouse recipe that already told the field which two knobs Conboy likes to turn.

Disclaimer: This article is news reporting and analysis of public company statements, interviews, and published research. It is informational only and is not medical advice, a recommendation to seek or avoid any injection, plasma exchange, or longevity clinic service, or an assessment of whether 1 Generation is safe or effective. Readers considering any aging treatment, off-label drug mix, or clinic procedure should consult a licensed physician who can review their history, medications, and the actual products involved. Figures, clinic counts, prices, and trial plans reflect the sources available as of August 28, 2026, and may change as Generation Lab, regulators, or independent researchers publish more.